Text Size: a  |   a 

Scottish Medicines Consortium Approves Zinbryta for NHS Treatment of RRMS Patients in Scotland

May 10, 2017

The United Kingdom’s National Institute for Health and Care Excellence (NICE) recommended using Zinbryta (daclizumab) to treat RRMS in England and Whales. Recently, Scotland received Scottish Medicines (SMC) approval for the National Health Service (NHS) to prescribe Zinbryta.

Zinbryta is a disease-modifying drug that modulates the effects caused by the body’s immune system response, which are believed to drive the central nervous system symptoms observed in MS patients.

Self-injections of this drug once a month has shown a reduction in the occurrence of relapses and MS disability progression. The drug offers a treatment option for patients who require high-efficacy therapies or who have contradictions to other treatments.

Results from the Phase 3 DECIDE and Phase 2b SELECT clinical trials have confirmed Zinbryta’s effectiveness and safety. This new modifying drug has been shown to reduce relapses by about 50%.

Zinbryta prescriptions is now recommended for those who have rapidly evolving severe RRMS, or for RRMS patients who do not respond to other disease modifying therapies. However, there are side effects to this drug, which patients should consider before taking this drug. Common side effects include infections or swelling of the chest, nose and throat, increased levels of liver enzymes, skin rash or eczma, depression and swollen lymph glands. More severe effects includes serious skin reactions and liver damage. However, they were reported to be less common during clinical trials.